Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Trending in China: Wholesale Mask Prices Fall Over 90% and Raw Materials Fall to Fraction of Peak Price
Trending in China: Can Douyin, China’s Version of TikTok, Help China’s LGBT Community?
India Asks Banned Chinese Apps 77 Questions Over Content Review and Data Security
Air Conditioner Maker Gree Warns Profit May Drop Sharply in First Half of 2020
Chipmaker SMIC Prepares for China’s Biggest Share Debut in a Decade
Hillhouse to pick stake in Shanghai-listed drug maker Joincare for $310m
Trending in China: Jack Ma Sells $8.2 Billion of Alibaba Shares — Good News for Philanthropy or Bad News for Tech Companies?
Didi to March Into 20 New Australian Cities Next Month
Underwater Robotics Maker Sublue Speeds Toward STAR Board Listing with New Funding
Suning.com Predicts Over $20 Million in Losses in First Half of 2020, Says Carrefour China Remains Profitable
Online Travel Leader Trip.com to Issue $500 Million in Convertible Bonds
Trending in China: Was the Driver Who Deliberately Crashed His Bus Killing 21 Evil or a Victim? Netizens Discuss
Foxconn Plans to Invest $1 Billion to Expand iPhone Production at Indian Factory: Reuters
Money-Losing Electric Carmaker Li Auto Files for U.S. IPO
Platform Serving China’s Takeout Delivery Workers Jumps 28% in Nasdaq Debut
SenseTime Builds AI Computing Platform in Shanghai Amid ‘New Infrastructure’ Push
WeRide to Test Fully Autonomous Vehicles in Guangzhou
Trending in China: Why Are Chinese Netizens Saying Kanye West Could be ‘China’s First’ U.S. President?
Trending in China: Will Weibo’s Fight Against Porn Have Other Unintended Side Effects
Tencent Leads $40 Million Investment in Online Art Educator
China Approves First Biosimilar of Foreign Drug, Breaking Roche Monopoly

By Wang Luyao and Tang Ziyi / Feb 27, 2019 06:16 PM / Business & Tech

China’s National Medical Products Administration announced Monday that it has approved the country's first biosimilar drug — a copy of Roche’s drug Rituxan for treatment for lymphoma.

Biosimilars are nearly identical copies of biologics -- medicines made from living cells that must be stored under special conditions— already approved by a regulator.

The biosimilar drug made by Fosun Pharma’s joint venture subsidiary Shanghai Henlius Biotech will break the monopoly of Switzerland’s Roche, which has been the only supplier of Rituxan in China.

In 2017, Rituxan accounted for 1.73 billion yuan ($258.6 million) of Roche’s China sales, after the drug was added into the government-backed insurance reimbursement scheme, said Fosun Pharma in a statement.


Share this article
Open WeChat and scan the QR code